# A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

> **NCT01216072** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1053 (actual)

## Conditions studied

- Relapsing Forms of Multiple Sclerosis

## Interventions

- **DRUG:** Fingolimod
- **DRUG:** Standard MS DMTs

## Key facts

- **NCT ID:** NCT01216072
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 1053 (ACTUAL)
- **Last updated:** 2014-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01216072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01216072, "A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01216072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*